Phenotypes associated with this allele

• Allele Symbol: Mpg^tm1Lds
• Allele Name: targeted mutation 1, Leona D Samson
• Allele ID: MGI:2675730
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mpg^tm1Lds/Mpg^tm1Lds	involves: 129P2/OlaHsd	MGI:4429604
hm2	Mpg^tm1Lds/Mpg^tm1Lds	involves: 129P2/OlaHsd * C57BL/6	MGI:2675731

Genotype
MGI:4429604

hm1

• Allelic Composition: Mpg^tm1Lds/Mpg^tm1Lds
• Genetic Background: involves: 129P2/OlaHsd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:47993 )

N • somatic hypermutation rates in memory B cells are normal

Genotype
MGI:2675731

hm2

• Allelic Composition: Mpg^tm1Lds/Mpg^tm1Lds
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

endocrine/exocrine glands

small pancreatic islets ( J:118148 )

• islet size is significantly reduced in STZ treated mutants compared to untreated controls

homeostasis/metabolism

increased circulating glucose level ( J:118148 )

• after a single high dose of streptozocin (SHDS), mutants have significantly lower blood glucose levels compared to treated controls, but higher levels than untreated mutants

• controls rapidly develop diabetes with blood glucose levels ~409 mg/dl compared to ~ 249 mg/dl for treated mutants or 150 mg/dl for untreated mutants

• levels are elevated a few days after treatment, recover, then mice become hyperglycemic at 6-10 weeks (>250 mg/dl glucose)

cellular

increased apoptosis ( J:118148 )

• SHDS-treated mutants show decreased staining for insulin in pancreatic islets and a few apoptosis-positive B cells compared to controls at 48 hours after treatment indicating partial protection from direct STZ cytotoxicity

immune system

autoimmune response ( J:118148 )

• with age, mutants show autoimmune destruction of the pancreas that is independent of STZ-treatment

• infiltrating T cells are observed in islet tissue of untreated 10 and 16 month old mutants

decreased susceptibility to autoimmune diabetes ( J:118148 )

• at 6-10 weeks after streptozocin (STZ), mutants do not show T cell infiltration which is indicative of early autoimmune diabetes

• T-cell depleted mutants treated with STZ do not develop overt diabetes compared to treated isotype controls; glucose levels do not increase above 150 mg/dl after 14 months

• after a glucose bolus T cell-deficient treated mutants display impaired glucose tolerance and blood glucose levels do not recover as quickly as untreated controls